Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

119.46 -0.32 (-0.27%)
Streaming Delayed Price Updated: 11:44 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
68 69 Next >
News headline image
Why Is Gilead Sciences (GILD) Stock Rocketing Higher Today
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.7% in the morning session after the company reported second-quarter 2025 results that topped Wall Street's expectations and... 
Via StockStory
Topics Earnings
News headline image
Gilead Lifts Annual Outlook As Yeztugo Launch Nears ↗
Gilead raised its 2025 earnings and sales outlook after posting better-than-expected Q2 results, led by strong HIV and oncology drug sales. 
Via Benzinga
News headline image
SoundHound AI, Ouster, Globalstar, Doximity, JFrog And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
Topics Artificial Intelligence
Gilead Stock Showered With Upgrades, Price Target Hikes After Upbeat Q2, Guidance Lift: Retail’s Turned Exuberant ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Gilead Sciences's Earnings Outlook ↗
 
Via Benzinga
News headline image
Discover the top S&P500 movers in Friday's pre-market session. ↗
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
News headline image
Gilead Sciences (GILD) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Gilead Sciences (NASDAQ:GILD) Beats Q2 Sales Targets
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 1.8% year on year to $7.08 billion. On the other hand, the... 
Via StockStory
News headline image
Will Gilead's Beat-And-Raise Help It Leapfrog Its 50-Day Line Ceiling? ↗
Gilead Sciences boosted its full-year outlook after beating expectations. Gilead stock is hitting a 50-day line ceiling. 
Via Investor's Business Daily
News headline image
Price Over Earnings Overview: Gilead Sciences ↗
 
Via Benzinga
News headline image
Gilead Sciences Announces Second Quarter 2025 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
How To Earn $500 A Month From Gilead Sciences Stock Ahead Of Q2 Earnings ↗
 
Via Benzinga
News headline image
Arcus (RCUS) Q2 Revenue Jumps 310% ↗
Via The Motley Fool
News headline image
Gilead Sciences Inc (NASDAQ:GILD) Meets Caviar Cruise Quality Investing Criteria ↗
The Caviar Cruise strategy identifies high-quality stocks like Gilead Sciences (GILD) for long-term investment, focusing on strong growth, ROIC, low debt, and solid cash flow. GILD excels in... 
Via Chartmill
Topics Economy
News headline image
Apple Jumps, Eli Lilly Crashes On Worst Day In 25 Years: What's Moving Markets Thursday? ↗
U.S. equities slipped midday Thursday as corporate earnings and fresh tariff announcements from President Donald Trump drove divergent moves in heavyweight names. 
Via Benzinga
Topics Government World Trade
News headline image
Gilead Sciences (GILD) Reports Q2: Everything You Need To Know Ahead Of Earnings
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
Upcoming Earnings Calls This Week: August 4th - August 10th, 2025
This week, from August 4th to August 10th, 2025, marks a busy period in the second-quarter earnings season, with hundreds of companies across various sectors scheduled to report their financial... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Tango (TNGX) Q2 Revenue Drops 52% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
GILEAD SCIENCES INC (NASDAQ:GILD) Shows Strong Technical Breakout Potential with High Ratings ↗
Gilead Sciences (GILD) shows strong technical breakout potential with a high Technical Rating (10) and Setup Rating (8), indicating upward momentum and consolidation before a possible breakout. 
Via Chartmill
News headline image
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter? ↗
The upgraded score means Gilead is now outperforming 96% of all stocks in terms of the most important stock-picking criteria. 
Via Investor's Business Daily
News headline image
Pheton Holdings Dismisses Rumors Of Acquisition By Gilead, But Retail’s Extremely Optimistic ↗
pheton-holdings-dismisses-rumors-of-acquisition-by-gilead 
Via Stocktwits
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗
Via Stocktwits
Topics Government
News headline image
Chinese Health Care Stock Pheton Holdings Collapses After Short Seller Warns Of Manipulation By 'Overseas Scammers' ↗
 
Via Benzinga
News headline image
Why Gilead Sciences Stock Slipped Today ↗
Changes in a federal healthcare authority could negatively impact one of the company's important businesses. 
Via The Motley Fool
News headline image
BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive ↗
The Supreme Court's Braidwood decision only concretized the power of the Department of Health and Human Services to decide what is necessary preventative care, rather than outright protecting... 
Via Stocktwits
News headline image
Visa, Disney, Blackstone And A Health Care Stock On CNBC's 'Final Trades' ↗
Visa, which will report third quarter results on Tuesday, July 29, is analyst Stephanie Link's final trade. 
Via Benzinga
News headline image
Why Gilead Sciences (GILD) Stock Is Up Today
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3% in the afternoon session after its long-acting HIV prevention injection, lenacapavir, received a recommendation for approval... 
Via StockStory
Topics Stocks World Trade
News headline image
Why Gilead Sciences Stock Just Popped ↗
Gilead stock is flashing "buy" in bright green letters. 
Via The Motley Fool
News headline image
Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales ↗
Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, exceeding prior estimates. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.